Evidence map›Paper›PMID 35122132›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2022

Evaluating an automated machine learning model that predicts visual acuity outcomes in patients with neovascular age-related macular degeneration.

Abdallah Abbas, Ciara O'Byrne, Dun Jack Fu, Gabriella Moraes, Konstantinos Balaskas, Robbert Struyven, Sara Beqiri, Siegfried K Wagner, Edward Korot, Pearse A Keane

Open access · hybridAbstract read
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Comparing code-free and bespoke deep learning approaches in ophthalmology.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Abdallah AbbasUniversity College London Medical School, London, UK. Abdallah.abbas.18@ucl.ac.uk.ORCID http://orcid.org/0000-0002-9035-5475
Ciara O'ByrneMoorfields Eye Hospital, London, UK.ORCID http://orcid.org/0000-0001-5172-0030
Dun Jack FuMoorfields Eye Hospital, London, UK.ORCID http://orcid.org/0000-0003-2852-6912
Gabriella MoraesMoorfields Eye Hospital, London, UK.ORCID http://orcid.org/0000-0003-3358-5861
Konstantinos BalaskasMoorfields Eye Hospital, London, UK.
Robbert StruyvenMoorfields Eye Hospital, London, UK.
Sara BeqiriUniversity College London Medical School, London, UK.
Siegfried K WagnerNIHR Biomedical Research Centre at Moorfields Eye Hospital, UCL Institute of Ophthalmology, London, UK.ORCID http://orcid.org/0000-0003-4915-4353
Edward KorotStanford University Byers Eye Institute, Palo Alto, CA, USA.ORCID http://orcid.org/0000-0002-5687-1564
Pearse A KeaneNIHR Biomedical Research Centre at Moorfields Eye Hospital, UCL Institute of Ophthalmology, London, UK.ORCID http://orcid.org/0000-0002-9239-745X
Moorfields Eye Hospital · GBUniversity College London · GBSmith-Kettlewell Eye Research Institute · USTrinity College Dublin · IE

Funding

Medical Research Council MR/T000953/1Medical Research Council MR/T019050/1moorfields eye charity career development award R190028Auk research & innovation future leaders fellowship MR/T019050/1
6 · The paper itself

Abstract

purposeNeovascular age-related macular degeneration (nAMD) is a major global cause of blindness. Whilst anti-vascular endothelial growth factor (anti-VEGF) treatment is effective, response varies considerably between individuals. Thus, patients face substantial uncertainty regarding their future ability to perform daily tasks. In this study, we evaluate the performance of an automated machine learning (AutoML) model which predicts visual acuity (VA) outcomes in patients receiving treatment for nAMD, in comparison to a manually coded model built using the same dataset. Furthermore, we evaluate model performance across ethnic groups and analyse how the models reach their predictions.

methodsBinary classification models were trained to predict whether patients' VA would be 'Above' or 'Below' a score of 70 one year after initiating treatment, measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. The AutoML model was built using the Google Cloud Platform, whilst the bespoke model was trained using an XGBoost framework. Models were compared and analysed using the What-if Tool (WIT), a novel model-agnostic interpretability tool.

resultsOur study included 1631 eyes from patients attending Moorfields Eye Hospital. The AutoML model (area under the curve [AUC], 0.849) achieved a highly similar performance to the XGBoost model (AUC, 0.847). Using the WIT, we found that the models over-predicted negative outcomes in Asian patients and performed worse in those with an ethnic category of Other. Baseline VA, age and ethnicity were the most important determinants of model predictions. Partial dependence plot analysis revealed a sigmoidal relationship between baseline VA and the probability of an outcome of 'Above'.

conclusionWe have described and validated an AutoML-WIT pipeline which enables clinicians with minimal coding skills to match the performance of a state-of-the-art algorithm and obtain explainable predictions.

Indexed as

Macular DegenerationWet Macular DegenerationAngiogenesis InhibitorsHumansIntravitreal InjectionsMachine LearningRanibizumabRetrospective StudiesTreatment OutcomeVascular Endothelial Growth Factor AVisual AcuityAngiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor AAnti-VEGFArtificial intelligenceAutomated machine learningModel interpretabilityNeovascular age-related macular degenerationOCT

Identifiers

PMID35122132
PMCPMC9325856
OpenAlexW4210695779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.